Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Aug 10:28:24-27.
doi: 10.1016/j.jdcr.2022.08.005. eCollection 2022 Oct.

Ocrelizumab-induced vulvovaginal pyoderma gangrenosum in a patient with relapsing-remitting multiple sclerosis

Annika Klumpp  1 , Felix Luessi  2 , Sinah Engel  2 , Beate Weidenthaler-Barth  1 , Detlef Becker  1 , Stephan Grabbe  1 , Hadrian Schepler  1
Affiliations
Case Reports

Ocrelizumab-induced vulvovaginal pyoderma gangrenosum in a patient with relapsing-remitting multiple sclerosis

Annika Klumpp et al. JAAD Case Rep. .
No abstract available

Keywords: MS, multiple sclerosis; PG, pyoderma gangrenosum; anti-CD20 agent; multiple sclerosis; ocrelizumab; pyoderma gangrenosum.

PubMed Disclaimer

Conflict of interest statement

Luessi received consultancy fees from Roche and support with travel cost from Teva Pharma.

Figures

Fig 1
Fig 1
Admission findings with extensive wound areas, perianal cavity, and gluteal undermining.
Fig 2
Fig 2
Tissue biopsy showed histological signs of an inflammatory reaction supporting diagnosis of pyoderma gangrenosum. A, Ulceration with diffuse mixed dermal infiltrates rich in neutrophils, hematoxylin-eosin stain, magnification, 50×. B, Superficial dermal accumulation of neutrophils surrounded by histiocytes and some giant cells, Hematoxylin-eosin stain, magnification, 200×.
Fig 3
Fig 3
Findings at discharge: significant reduction of the wound areas with adhesion of the wound cavities and secondary wound healing.
See this image and copyright information in PMC

References

    1. Kamm C.P., Uitdehaag B.M., Polman C.H. Multiple sclerosis: current knowledge and future outlook. Eur Neurol. 2014;72(3-4):132–141. doi: 10.1159/000360528. - DOI - PubMed
    1. Montalban X., Hauser S.L., Kappos L., et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209–220. doi: 10.1056/NEJMoa1606468. - DOI - PubMed
    1. Breneman A.N., Eber A.E., Haque H., Levine L. Vulvovaginal pyoderma gangrenosum in a patient treated with ocrelizumab for multiple sclerosis. J Low Genit Tract Dis. 2022;26(2):189–191. doi: 10.1097/LGT.0000000000000661. - DOI - PubMed
    1. Ahronowitz I., Harp J., Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol. 2012;13(3):191–211. doi: 10.2165/11595240-000000000-00000. - DOI - PubMed
    1. Thompson A., Brenda B., Barkhof F., Carroll W. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–173. doi: 10.1016/S1474-4422(17)30470-2. - DOI - PubMed

Publication types

LinkOut - more resources